<DOC>
	<DOCNO>NCT01660321</DOCNO>
	<brief_summary>A pharmacokinetic tolerance study Natroba ( spinosad ) Topical Suspension , 0.9 % pediatric subject 6 month 4 year age active head louse infestation .</brief_summary>
	<brief_title>Pharmacokinetic ( PK ) Tolerance Study Natroba Topical Suspension Pediatrics With Active Head Lice Infestation</brief_title>
	<detailed_description>A Postmarketing Requirement Protocol , multicenter , open-label study pediatric subject 6 month 4 year age active head louse infestation design determine topical absorption safety Natroba ( spinosad ) Topical Suspension , 0.9 % single , 10 minute treatment spinosad ( Spinosyn A Spinosyn D ) benzyl alcohol .</detailed_description>
	<mesh_term>Parasitic Diseases</mesh_term>
	<mesh_term>Lice Infestations</mesh_term>
	<criteria>1 . Male female , 6 month 4 year age . 2 . Subjects must active louse infestation include live louse . 3 . Individuals otherwise good general health , free systemic dermatologic disorder , opinion Principal Investigator designee , would interfere study result increase risk adverse event . 4 . A parent ( guardian ) must sign Informed Consent Form allow child participate study . 5 . Subjects must available stay clinic blood draw . Parents guardian must available stay clinic , subject , entire duration study . 6 . Subjects must vein capable insertion Heplock catheter withstand multiple blood draw determine Principal Investigator qualify phlebotomist . 7 . Normal value ( screen ) serum chemistry hematology subject , unless principal Investigator qualify medical designee determine abnormal value clinically significant . 1 . History irritation sensitivity pediculicide hair care product ingredient . 2 . History know allergy sensitivity topical anesthetic include lidocaine prilocaine . 3 . History allergy sensitivity Heparin . 4 . Systemic disease could interfere result study determined Principal Investigator designee . 5 . Any condition illness , opinion Investigator designee , may compromise objective protocol safety subject . 6 . The use antibiotic systemic medication within 2 week screen visit , opinion Investigator designee could interfere outcome study . 7 . Participation previous drug study within past 30 day . 8 . Individuals visible skin/scalp condition ( active louse infestation ) treatment site would interfere evaluation accord opinion Investigator designee . 9 . Parents guardian , opinion Investigator , understand child 's requirement study participation and/or may likely exhibit poor compliance .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Pediculosis capitis</keyword>
	<keyword>Head Lice</keyword>
</DOC>